Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRNA injection aims to strengthen bladder control in women

NCT ID NCT06247241

Disease control Sponsor: Versameb AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was testing a new drug called VMB-100, which is an mRNA that tells muscle cells to produce a protein (IGF-1) to help repair the urethra sphincter. The goal was to improve muscle function and reduce urine leakage in women with moderate stress urinary incontinence. The study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main inclusion criteria: * Pre- or peri-menopausal female subject between 18 and 55 years of age * Body mass index (BMI) of 19 to 35 kg/m2 * Active SUI of moderate severity for at least 6 consecutive months documented in medical history * Refractory to standard of care measures * Must not be pregnant, lactating, or actively trying to become pregnant. Main exclusion criteria: * Any concurrent condition or any clinically significant abnormality at Screening which in the opinion of the Investigator may affect the interpretation of safety or efficacy data or which otherwise contradicts participation in a clinical study with VMB-100 * Unwilling to undergo transvaginal sonography or cystoscopy * Urodynamic detrusor overactivity * History of urinary urge incontinence of neurogenic etiology. * History of or planning for pelvic radiation. * History of use of any bulking agent or Botox to treat SUI in the past 12 month. * History of urethral sling, anterior prolapse repair, and/or other SUI procedures or surgical procedures affecting continence. * Taking any medications that are known to have an effect on urinary continence or medications that may exacerbate incontinence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate stress urinary incontinence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

female stress incontinence Urinary Incontinence, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stress urinary incontinence

More trials for these conditions

Other studies related to the condition(s) this trial covers.